Astrazeneca (AZN) confirmed Friday in an emailed statement to MT Newswires that its breast cancer treatment Enhertu and cancer treatment Orpathys have been added to China's National Reimbursement Drug List (NRDL)
The inclusion in the NRDL grants state-run medical insurance coverage to the cancer treatments, starting Jan. 1, 2025, multiple media outlets reported Thursday.
Enhertu is among 91 drugs that will be added to the NRDL, including oncology drugs from drugmakers including Johnson & Johnson (JNJ), Merck (MRK), Bristol Myers (BMY), Roche and Sanofi (SNY), Bloomberg said and added that drugmakers have to accept price cuts, averaging 63%, to secure inclusion on the list.
Zai Lab (ZLAB) said Thursday its AUGTYRO was also included in the NRDL to treat adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。